Priya Patel
TLDR:
- Cagent Vascular has raised over $30m in funding to expand its Serration Angioplasty Technology product portfolio.
- The Serranator balloon catheter is designed to treat peripheral artery disease and chronic limb-threatening ischemia.
Article Summary:
Cagent Vascular has secured a significant amount of funding through a series C financing round led by US Venture Partners to accelerate the adoption of its Serration Angioplasty Technology product portfolio. The company aims to enhance the commercial reach of the Serranator PTA serration balloon catheters, which have been used in over 10,000 procedures to treat peripheral artery disease (PAD). The Serranator is specifically designed to address PAD and chronic limb-threatening ischemia, with a unique mechanism of action that promotes arterial expansion and lumen gain. It has received approval from the US Food and Drug Administration and limited distribution in Europe with CE Mark approval.
A study published in the Journal of Endovascular Therapy demonstrated the effectiveness of the Serranator in reducing elastic recoil in below-the-knee lesions, offering potential benefits for patients with CLTI. The funding will enable Cagent Vascular to expand its commercial operations and provide healthcare providers with greater access to this innovative technology. US Venture Partners expressed confidence in the serration angioplasty approach and emphasized the importance of innovation in addressing the needs of PAD patients.
The investment from US Venture Partners, Blue Ridge Medical, and other investors will support Cagent Vascular in furthering its mission to improve outcomes for patients with vascular diseases. This funding will play a crucial role in driving the growth and development of the Serranator technology, paving the way for advancements in angioplasty treatments for PAD and related conditions.
